On 23 August 2017, orphan designation (EU/3/17/1913) was granted by the European Commission to Neupharma S.r.l., Italy, for teicoplanin for the treatment of cystic fibrosis.
The sponsor’s address was updated in April 2021.
Treatment of cystic fibrosis
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.